COMPLETED

A Study of LY3841136 in Overweight and Obese Participants

Talk to us

Conditions

ObesityOverweightSafetyTolerabilityBody weight

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.

Official Title

A Multiple Dose Combination Study to Evaluate the Safety and Tolerability of Tirzepatide and LY3841136 in Overweight and Obese Participants

Quick Facts

Study Start:2024-04-03
Study Completion:2025-09-29
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT06345066

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Male and female participants who are overtly healthy as determined by medical evaluation
  2. * Have a stable body weight and Body Mass Index in range of 27 to 45 kilogram per meter square (kg/m²).
  3. * Have clinical laboratory test results within normal reference range
  4. * Have venous access sufficient to allow for blood sampling
  5. * Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
  1. * Have type 1 or type 2 diabetes mellitus
  2. * Have an abnormal 12-lead electrocardiogram (ECG)
  3. * Have a history or presence of psychiatric disorders
  4. * Have abnormal blood pressure and pulse rate
  5. * Are currently enrolled in another clinical study trial involving medical research or have participated within the last 30 days in a clinical study involving an investigational product.

Contacts and Locations

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
STUDY_DIRECTOR
Eli Lilly and Company

Study Locations (Sites)

Fortrea Clinical Research Unit
Daytona Beach, Florida, 32117
United States
Fortrea Clinical Research Unit
Dallas, Texas, 75247
United States
Fortrea Clinical Research Unit
Madison, Wisconsin, 53704
United States

Collaborators and Investigators

Sponsor: Eli Lilly and Company

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-04-03
Study Completion Date2025-09-29

Study Record Updates

Study Start Date2024-04-03
Study Completion Date2025-09-29

Terms related to this study

Keywords Provided by Researchers

  • Safety
  • Tolerability
  • Body weight

Additional Relevant MeSH Terms

  • Obesity
  • Overweight